Royal Bank Of Canada Forecasts Strong Price Appreciation for Hinge Health (NYSE:HNGE) Stock

Hinge Health (NYSE:HNGE) had its target price raised by Royal Bank Of Canada from $110.00 to $135.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank Of Canada‘s price target would indicate a potential upside of 16.01% from the company’s previous close.

HNGE has been the subject of several other reports. Barclays boosted their target price on shares of Hinge Health from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Morgan Stanley lifted their price objective on shares of Hinge Health from $72.00 to $108.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Wall Street Zen downgraded shares of Hinge Health from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Bank of America assumed coverage on shares of Hinge Health in a research note on Tuesday, September 29th. They set a “buy” rating and a $110.00 target price on the stock. Finally, Weiss Ratings cut Hinge Health from a “hold (c)” rating to a “hold (c-)” rating in a research report on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Hinge Health currently has an average rating of “Moderate Buy” and a consensus price target of $115.20.

Hinge Health Price Performance

NYSE:HNGE traded up $0.89 during trading hours on Tuesday, reaching $116.37. The company had a trading volume of 330,439 shares, compared to its average volume of 1,618,864. Hinge Health has a 1-year low of $30.08 and a 1-year high of $118.86. The firm has a market cap of $9.39 billion, a PE ratio of 91.44 and a beta of 1.37. The business’s 50 day moving average price is $98.66 and its 200-day moving average price is $67.35.

Hinge Health (NYSE:HNGE) last released its quarterly earnings data on Monday, November 2nd. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.27 by $0.44. The business had revenue of $234.97 million for the quarter. Hinge Health had a return on equity of 51.60% and a net margin of 15.15%. The company’s revenue for the quarter was up 52.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.02) EPS. On average, analysts expect that Hinge Health will post 1.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Chairman Gabriel Mecklenburg sold 250,000 shares of Hinge Health stock in a transaction on Friday, September 11th. The shares were sold at an average price of $88.97, for a total value of $22,242,500.00. Following the sale, the chairman owned 250,000 shares of the company’s stock, valued at approximately $22,242,500. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Perez sold 150,000 shares of the business’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $89.44, for a total transaction of $13,416,000.00. Following the completion of the sale, the chief executive officer directly owned 35,470 shares of the company’s stock, valued at approximately $3,172,436.80. The trade was a 80.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,024,581 shares of company stock worth $95,632,761. Corporate insiders own 18.92% of the company’s stock.

Institutional Trading of Hinge Health

A number of institutional investors and hedge funds have recently modified their holdings of the stock. 11.2 Capital Management LLC purchased a new position in Hinge Health in the 2nd quarter valued at about $204,566,531. Assenagon Asset Management S.A. increased its stake in Hinge Health by 2,141.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,854,922 shares of the company’s stock worth $180,373,000 after buying an additional 1,772,182 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Hinge Health by 169.7% during the second quarter. Wellington Management Group LLP now owns 1,205,584 shares of the company’s stock valued at $100,063,000 after acquiring an additional 758,594 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Hinge Health by 225.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,163,187 shares of the company’s stock valued at $44,852,000 after acquiring an additional 806,007 shares during the last quarter. Finally, Estuary Capital Management LP purchased a new position in shares of Hinge Health in the first quarter valued at approximately $15,201,000.

Key Headlines Impacting Hinge Health

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Record Q3 results beat expectations. Hinge Health reported third-quarter revenue of approximately $235.0 million, up 52.4% year over year and ahead of the roughly $224.8 million consensus estimate. Adjusted earnings were reported at $0.71 per share, exceeding consensus forecasts ranging from $0.27 to $0.63. The company also posted a 15.15% net margin and 51.6% return on equity. Hinge Health reports record third quarter 2026 financial results
• Positive Sentiment: Revenue guidance was raised above Wall Street expectations. Hinge Health forecast fourth-quarter 2026 revenue of $249.0 million to $251.0 million, versus consensus of $239.2 million. Full-year 2026 revenue guidance of $879.0 million to $881.0 million also exceeded the $858.5 million consensus estimate. Hinge Health 2026 revenue outlook
• Positive Sentiment: Analysts raised their targets and maintained bullish ratings. Canaccord Genuity increased its price target from $105 to $134 and assigned a “buy” rating. Stifel Nicolaus raised its target from $130 to $135 and also rated the stock “buy,” implying roughly 16% to 17% potential upside from recent levels.
• Positive Sentiment: Future growth initiatives provided an additional catalyst. Management is targeting an integrated gastrointestinal program for summer 2027, supporting the broader expansion of Hinge Health’s digital-care platform.
• Neutral Sentiment: The stock is trading near its 52-week high after a substantial advance, with a high valuation reflected in a price-to-earnings ratio near 90. Although the earnings and outlook were strong, the elevated valuation may limit further gains if results do not continue to exceed already-high expectations.

Hinge Health Company Profile

Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care programs designed to help members manage pain, improve mobility and reduce the need for more costly or invasive treatments.

Its platform combines personalized exercise therapy, behavioral support, education and access to clinical professionals. Hinge Health also uses technologies such as motion-sensing wearable devices and artificial intelligence to help guide exercises, monitor progress and tailor care plans to individual needs.

Hinge Health primarily serves employers and health plans, which offer its programs to eligible members in the United States.